

1 **Supplementary material**

2 **0.1 Missing values and sample sizes per model**

3 Despite the aim of the study to run all seven models in this study on the
4 same data set, we were faced with the challenge that differing requirements
5 for each model with respect to missing values made an adjustment of sample
6 sizes per model necessary. Combat [Fortin2017, Fortin2018] accepts missing
7 values, and could be thus run on the full data set. In contrast, ComBat Gam
8 [pomponio2020] does not. Thus, for ComBat Gam all subjects with a missing
9 value in any of the 35 regions had to be excluded, which lead to a sample size
10 reduction from 391 to 370 individuals for the training set, and from 168 to 156
11 individuals for the healthy test set. The normative modeling process is performed
12 region wise and independently, thus only the subjects that contained missing
13 subjects for that particular region were deleted.

14 **0.2 Model convergence, effective sample size and \hat{R}**

15 For the present project, each model run entailed a Monte-Carlo sampling process
16 of 4000 iterations in Stan, of which 2000 were disregarded as warm up. Stan
17 allows for the computation of a number of diagnostics on the quality of the
18 Markov Chain Monte Carlo (MCMC) sampling process, which are reported in
19 the following.

20 **0.3 Model convergence**


21 Markov chains are defined to only generate samples from the target distribution
22 after the distribution has converged to an equilibrium, thus, when the distribution
23 is considered to be the target density. In theory, this equilibrium can only
24 asymptotically be reached, as the number of draws is theoretically infinite.

25 In practice, the number of draws has to be a-priori set to a finite amount.
26 As a consequence, the actual and convergence to the target density has to
27 be monitored [carpenter2017stan, Gelman2015, stan2019]. One way to
28 monitor the convergence of a chain to equilibrium is to compare the chain to
29 other randomly initialized chains. This can either be done via visual inspection,
30 or using the scale reduction statistic, \hat{R} [gelman1992inference]. For visual
31 inspection, the trace plots over 4 chains for all parameters can be found in Figs.
32 1a, 2a , 3a, 4a, 5a, 6a, 7a. The \hat{R} values, indicating the convergence of chains,
33 can be found in Figs. 1b, 2b , 3b, 4b, 5b, 6b, 7b for each model, respectively. All
34 \hat{R} values are <1.05 , which provides good evidence that all chains have reached
35 convergence and can therefore be considered to provide unbiased samples from
36 the target density.

37 **0.4 Statistical comparison of measures of model perfor-** 38 **mance**

39 All comparisons regarding measures of model performance were performed using
40 two-way ANOVAs including the factors model (HBLM, HBGPM, Combat Gam,
41 ComBat, ComBat without covariates, residuals, raw data) and set (train, test).
42 Post hoc tests were performed using Tukey tests and corrected for multiple
43 comparisons. Parametric tests such as ANOVA were deliberately chosen over
44 their non-parametric equivalents, since deviations from gaussianity were negligible
45 in the present data set and in the authors' opinion, the substantial loss of power
46 with the choice of non-parametric tests does not scale with the potential threat
47 of violated modeling assumptions such as homoscedasticity and gaussianity.

Post-warmup iteration - Hierarchical Bayesian Linear Model




(a) Trace plots

(b) \hat{R}

Figure 1: Hierarchical Bayesian Linear Model

Post-warmup iteration - Hierarchical Bayesian Gaussian Process I




(a) Trace plots

(b) \hat{R}

Figure 2: Hierarchical Bayesian Gaussian Process Model

Post-warmup iteration - ComBat Gam Model




(a) Trace plots

(b) \hat{R}

Figure 3: ComBat Gam Model

Post-warmup iteration - ComBat Model



(a) Trace plots

(b) \hat{R}

Figure 4: ComBat Model




Figure 5: ComBat w/o covariates Model




Figure 6: Residuals Model




Figure 7: Raw Data Model

48 0.4.1 Effective sample size

49 One characteristic of MCMC methods is that samples will be auto- or anti-
50 correlated within a chain, leading to a reduction of precision in the estimates of
51 posterior quantities [geyer2011introduction]. Stan uses the auto correlation
52 ρ_t between samples n and $n+t$ with lag t to estimate the effective samples size
53 N_{eff} of independent samples in the chain. N_{eff} is considered to have the same
54 estimation power as N correlated samples and is then used, rather than N , to
55 estimate precision and error measures [stan2019]. N_{eff} for all models can be
56 found in Figs. 8a, 8b, 8c, 8d, 8e, 8f, 8g.

57 0.5 Results

58 0.6 Correlation between true and predicted value

59 Correlations between true and predicted values for the HBLM and HBGPM are
60 expressed in terms of the correlation coefficient ρ , calculated separately for each
61 region. ρ ranged from 0.60 to 0.84 in the training and 0.55 to 0.80 in the test set.
62 Overall, for just the Bayesian models, correlations were higher in the training
63 set and dropped in the test set (training set, across all regions: $\bar{\rho}_{HBLM} = 0.73$,
64 $SE = 0.05$; $\bar{\rho}_{HBGPM} = 0.75$, $SE = 0.06$; test set: $\bar{\rho}_{HBLM} = 0.69$, $SE = 0.06$;
65 $\bar{\rho}_{HBGPM} = 0.69$, $SE = 0.06$, $F[1, 136] = 18.82$, $p < 0.0001$). Correlations did
66 not differ significantly between the HBLM and HBGPM. ($F[1, 136] = 2.16$, $p =$
67 0.14).

68 Comparisons to the other, non-Bayesian models showed that ρ was signifi-
69 cantly higher for our models that included *site* as a predictor for with all other
70 models in which *site* was harmonized for prior to running the normative models,
71 both for training and test set (t-test *HBLM* and any other model $p < 0.001$,
72 t-test *HBGPM* and any other model $p < 0.001$, both for training and test set.)
73 The full distribution of the correlation coefficient ρ for all 35 regions per model

74 can be found in Fig 3a, main text. In addition, a test comparing the performance
 75 of all models for all regions (Bayesian and non-Bayesian) showed that predictions
 76 made from training data were not overall more accurate than predictions from
 77 the test data (main effect *set*, $F[1, 476] = 0.30$, $p = ns$, interaction *set* \times *model*,
 78 $F[1, 476] = 3.50$, $p = 0.002$). Further inspection showed that this might have
 79 been caused by the *residuals*, the *ComBat w/o covariates* and the *ComBat*
 80 model, where the test set performed *better* than the training set, canceling out
 81 performance benefits of the training data in the HBLM and HBGPM (see also
 82 Fig. 3a, main text).

83 0.7 Standardized Root Mean Squared Errors

84 We further evaluated the fit of the models by calculating the Standardized Root
 85 Mean Squared Error (SRMSE) between true values and predicted values per
 86 model per region. As expected, the SRMSE was larger for the test set ($M =$
 87 0.083) and smaller for the training set ($M = 0.080$, $[F(1, 134278) = 59.28$, p
 88 $< 0.001]$). For both the training and the test set, the Bayesian models showed
 89 smaller SRMSEs than all other models across all regions ($p < 0.001$; training
 90 set: $SR\bar{M}SE_{HBGPM} = 0.06$, $SE = 0.005$; $SR\bar{M}SE_{HBLM} = 0.06$, $SE = 0.005$;
 91 $SR\bar{M}SE_{ComBatGam} = 0.11$, $SE = 0.01$; $SR\bar{M}SE_{residuals} = 0.09$, $SE = 0.002$;
 92 $SR\bar{M}SE_{ComBat} = 0.08$, $SE = 0.007$, $SR\bar{M}SE_{ComBat-w/o-covariates} = 0.09$, SE
 93 $= 0.002$; $SR\bar{M}SE_{rawdata} = 0.08$, $SE = 0.005$; test set: $SR\bar{M}SE_{HBGPM} = 0.06$,
 94 $SE = 0.005$; $SR\bar{M}SE_{HBLM} = 0.07$, $SE = 0.006$; $SR\bar{M}SE_{ComBatGam} = 0.12$,
 95 $SE = 0.01$; $SR\bar{M}SE_{residuals} = 0.09$, $SE = 0.005$; $SR\bar{M}SE_{ComBat} = 0.08$, SE
 96 $= 0.009$; $SR\bar{M}SE_{ComBat-w/o-covariates} = 0.09$, $SE = 0.005$; $SR\bar{M}SE_{rawdata}$
 97 $= 0.085$, $SE = 0.007$). Neither in the training nor the test set did the Bayesian
 98 models differ from each other (training set: contrast *HBLMR* - *HBLM*, $t =$
 99 2.33 , $p = ns.$; test set: contrast *HBLMR* - *HBLM*, $t = 1.14$, $p = ns.$). We also

100 observed that both in the training and test set, the SRMSE of *ComBat w/o*
101 *covariates* did not differ from the SRMSE of the *residuals* (training set: contrast
102 *ComBat w/o covariates - residuals*, $t = 0.69$, $p = ns.$; test set: contrast *ComBat*
103 *w/o covariates - residuals*, $t = -1.70$, $p = ns.$. The full distribution of SRMSE
104 for all 35 regions per model can be found in Fig 3b, main text.

105 0.8 Explained variance

106 Analysis of the proportion of variance explained $EV = \frac{\sigma_{\hat{y}-y}^2}{\sigma_y^2}$ per model per region
107 were in line with the results reflected in ρ and SRMSE. EV was higher for the
108 *HBLM* and *HBGPM*, with an average of 0.56 (*HBGPM*, range: 0.35-0.70) and
109 0.53 (*HBLM*, range 0.35 - 0.67) for the training set and 0.50 (*HBGPM*, range
110 0.31 - 0.63) and 0.48 (*HBLM*, range 0.28 - 0.60) for the test set across all cortical
111 regions. The proportion of explained variance was substantially lower for the
112 comparison models, with the ComBat and the ComBat Gam model performing
113 best out of the comparison models, with an average of 0.31 for ComBat model
114 for the training set (range: 0.00 - 0.51) and 0.33 for the test set (range -0.02 -
115 0.58) across cortical regions, and an average of 0.31 for ComBat Gam for the
116 training set (range: -0.01 - 0.51) and 0.22 for the test set (range 0.03 - 0.46) but
117 showing lower EV than the Bayesian models. Predictions derived from *residuals*
118 and *ComBat w/o covariates* showed even lower EV, with *residuals* explaining an
119 average of 0.07 for the training set (range: 0.00 - 0.15) and 0.11 for the test set
120 (range 0.00 - 0.20) across cortical regions, and *ComBat* explaining an average
121 of 0.09 for the training set (range: 0.00 - 0.17) and 0.12 for the test set (range:
122 0.00 - 0.25) across cortical regions. Thus, the *ComBat w/o covariates*, *ComBat*
123 *and residuals* model performed even worse than predictions derived from *raw*
124 *data*, which showed an average EV of 0.21 in the training set (range: 0.00 -0.46)
125 and 0.20 in the test set (range 0.00 - 0.44) across cortical regions. These results

126 include the interesting finding that the test set shows slightly higher EVs than
127 the training set for all comparison models. An overview over the distribution of
128 explained variance for training and the test set for all 35 regions for all models
129 can be found in Fig. 3c, main text.

130 0.9 Log likelihood

131 The point-wise log likelihoods (LL) between the true and predicted were calcu-
132 lated for each data point, summed up per model across regions and averaged
133 y the number of individuals in training and test set per model, respectively.
134 The averaged summed LL across regions was closer to zero for the nonlinear
135 Bayesian model than for the linear Bayesian model, both for the training and the
136 test set ($\sum \frac{1}{n_{test}} LL_{HBGPM}$, test set: -1.109, $\sum \frac{1}{n_{test}} LL_{HBLM}$ test set: -1.121;
137 $\sum \frac{1}{n_{train}} LL_{HBGPM}$, training set: -1.020, $\sum \frac{1}{n_{train}} LL_{HBLM}$, training set: -1.05.
138 LL values were less close to zero for all comparison models, with the *Combat*
139 model performing best for among those models, followed by the *raw data* model,
140 the *residuals* model and the *ComBat w/o covariates* model (an overview of the
141 log likelihood for all models is given in Tab. 4, main text) The distribution of
142 the log likelihood for all regions is given in Fig. 3d, main text.

143 0.10 Effect sizes for site: Raw data and after correction 144 with models

145 Effect sizes in from of in form of partial η^2 and corresponding p values for raw
146 data and after correction with models. Please see also a commentary on the use
147 of effect sizes for site effect correction in the main text.

Raw data	partial η^2	p for site
Training set	0.58	<0.0001
Test set	0.55	<0.0001
Autism test	0.51	<0.0001

Table 1: Effect sizes for site, raw data.

Test set (controls)	partial η^2	p for site
HBGPM	0.08	0.03
HBLM	0.17	0.06
ComBat Gam	0.15	0.2
Combat	0.04	0.99
Combat w/o Sex & Site	0.05	0.98
Residuals	0.04	0.99


Table 2: Effect sizes for site after correction with various models, control test set.

Training set (controls)	partial η^2	p for site
HBGPM	<0.001	1
HBLM	<0.001	1
ComBat Gam	0.03	0.96
Combat	0.01	0.99
Combat w/o Sex & Site	0.06	0.2
Residuals	0.06	0.3


Table 3: Effect sizes for site after correction with various models, control training set.

Autism test set	partial η^2	p for site
HBGPM	0.19	0.04
HBLM	0.08	0.01


Table 4: Effect sizes for site after correction with HBLM and HBGPM, autism test set.




(a) Hierarchical Bayesian Linear Model (b) Hierarchical Bayesian Gaussian Process Model



(c) Model ComBat w/o covariates. (d) Model ComBat w *age/sex* preserved



(e) Residuals Model (f) Raw data Model



(g) ComBat Gam Model

Figure 8: Effective sample sizes N_{eff} for all parameters